What's happening
Writing a plain-English summary… Track this bill to get it by email.
Why it matters
Albany, before your first meeting.
Every bill that moved yesterday, summarized in a sentence and ranked by impact. The Albany Scorecard follows on Sundays.
Free. Unsubscribe in one click. Want alerts on specific bills? Create an account.
Who cares
Headline styles
Sponsors
No co-sponsors yet.
History
- Substituted by A6809
- Ordered to third reading cal.1778
- Committee discharged and committed to rules
- Referred to investigations and government operations
Companion bill
The same bill in the other chamber. A bill becomes law when one version passes both houses and the governor signs it, so either number can carry it.
Relates to extending the authorization of NYC to provide a biotechnology credit against the general corporation tax, unincorporated business tax, and banking corporation tax of such city
Signed by Governor · Sponsor David Weprin
Full text
The text isn't available here yet. Check nysenate.gov.
Sponsor's memo
BILL NUMBER:S4681
Title of bill
An act to amend the tax law, in relation to extending the authorization of any city having a population of one million or more to provide a biotechnology credit against the general corporation tax, unincorporated business tax, and banking corporation tax of such city
Purpose or general idea of bill
The bill extends amends paragraph 5 of subdivision d of section 1201-a of the tax law to allow the City of New York to extends its existing Biotechnology Credit for another three years from January 1, 2016 through December 31, 2018.
Summary of specific provisions
The bill extends amends paragraph 5 of subdivision d of section 1201-a of the tax law to allow the City of New York to extends its existing Biotechnology Credit for another three years from January 1, 2016 through December 31, 2018.
Justification
With 9 world-class research institutions, 26 medical centers, 175 hospitals, and an unparalleled talent pool, New York City has a natural advantage in the bioscience industry. Yet it lags behind other cities, such as Boston and San Diego, in the commercialization of new technologies. The credit targets the first state of commercialization, where the discoveries of basic science are investigated for their commercial properties. The credit is part of a policy to create an industry with sufficient size and density such that it becomes a good place to make a career in biotech and to locate the kind of ancillary services that the industry needs. This credit works in conjunction with the recent development of laboratory space at the East River Science Park, and BioBAT at the Brooklyn Army Terminal. These spaces, along with other facilities, provides approximately 2 million square feet of laboratory space in the City. The credit is complementary to New York State's Qualified Emerging Technology Companies Credit. For tax year 2010 the city received 23 applications for $2,050,565 in biotechnology credits.
A taxpayer is entitled to a credit if the company: 1) is a qualified emerging technology company engaging in biotechnologies, 2) has no more than one hundred full-time employees, of which at least seventy-five percent are employed in the city, 3) has a ratio of research and development funds to net sales of at least six percent, 4) has gross revenues not exceeding twenty million dollars, including affiliates, and 5) has annual sales not exceeding ten million dollars.
Prior legislative history
new bill
Fiscal implications
none, this bill will extend the already existing Biotechnology Credit for another three years
Effective date
immediately
Summaries, headlines and scores are AI-generated from the official bill text. How we score bills. Source: NYS Open Legislation.